Aimed Bio
Seoul, Seoul-t'ukpyolsi, South Korea, Asia
Overview
Aimedbio is a pharmaceutical manufacturing company that provides therapeutic systems and medicines for neuro-oncological and degenerative diseases, enabling patients with refractory brain disease, including cancer, to have an improved quality of life.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 4
Sector focus
- Health Care
- Medical
- Therapeutics
Investment portfolio
- Inocras
Participated · Series B · Aug 2026
Inocras develops whole-genome sequencing and proprietary bioinformatics solutions to translate comprehensive genomic data into curated, clinically actionable insights. Its oncology offerings include CancerVision™ for comprehensive tumor profiling and MRDVision™ for molecular residual disease detection, with automated interpretation capabilities. The company operates a CLIA/CAP-certified laboratory and reports real-world clinical adoption across Asia, with its solutions used by more than 100 cancer institutions and in thousands of patient cases. Inocras has established a significant commercial presence in Hong Kong and supports approximately thirty hospitals in South Korea. The company has collaborated with researchers at the Broad Institute to analyze whole-genome data from The Cancer Genome Atlas, informing broader use of standardized whole-genome analysis. The recent fundraise brought total funding to approximately $100 million to support further commercial expansion, particularly into the United States.